Watchful Waiting On Drug Prices In Part D
This article was originally published in RPM Report
CMS is shaking things up in Medicare Part B with a proposed demonstration project to test alternative reimbursement models for prescription drugs. But in Part D, CMS is taking more of a wait-and-see approach – at least in the annual update to the rules for bids on offering the insurance benefit.
You may also be interested in...
Former FDA Deputy Commissioner suggest Vaccine-For-Children model for high value drug purchasing programs during Johns Hopkins drug pricing conference. Bundled payments in Part D is another option put on the table. Medicare head Cavanaugh explains why that option is much harder to accomplish.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.